𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder

✍ Scribed by Franca Centorrino; Adam L. Meyers; Jonna Ahl; Stephanie L. Cincotta; Leslie Zun; Angela H. Gulliver; Bruce J. Kinon; John P. Houston

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
114 KB
Volume
22
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To determine the effect of intramuscular (IM) olanzapine in severely agitated patients.

Methods

This was an open‐label multicenter 1‐week observational study of IM olanzapine treatment in severely agitated inpatients and psychiatric emergency services with bipolar mania (n = 22) or schizophrenia (n = 52). Mean change from baseline to 2 h post‐first injection (LOCF) in agitation was assessed by PANSS‐Excited Component (PANSS‐EC) (score range: 5–35 points) mean change from baseline to 15, 30, 45, 60, 90, and 120 min post‐first injection, and visit‐wise mean changes from mixed‐model repeated measures analysis of variance. Kaplan–Meier survival curve analyses estimated time to categorical response (rating of ≤3 points each PANSS‐EC item).

Results

Two hours post‐injection of olanzapine (mean dose = 9.9 mg), patients exhibited mild calmness and agitation was significantly reduced by 19.2 ± 1.0 points (p < 0.001) (mean baseline = 29.0). Over 90% of the patients received only one injection in the first 24 h and 50% had a categorical response within 30 min.

Conclusions

Severely agitated patients responded rapidly after a single injection of olanzapine with mild levels of sedation and without serious treatment‐emergent adverse events. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

A pilot study of intramuscular ziprasido
A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia
✍ Shlomo Brook 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

Ziprasidone is a novel antipsychotic which, in oral formulation, has been shown to be effective and well tolerated in the treatment of acute psychosis. This pilot study examined the efficacy and tolerability of the intramuscular (IM) formulation and the transition from IM to oral ziprasidone in pati

A comparison of the efficacy and safety
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration
✍ C. W. Ritchie; E. Chiu; S. Harrigan; S. Macfarlane; M. Mastwyk; G. Halliday; H. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 3 views

Background Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effect